News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Business
Ipsen’s 2009 Results and Objectives
March 1, 2010
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
PARIS--(BUSINESS WIRE)--Regulatory News: The Board of Directors of Ipsen (Paris: IPN), chaired by Jean-Luc Bélingard, met on 26 February 2010 to review the Group’s results for 2009, published today.
Twitter
LinkedIn
Facebook
Email
Print
Earnings
Europe
Ipsen Biopharmaceuticals, Inc.
MORE ON THIS TOPIC
Collaboration
Crescent, Kelun-Biotech Swap Therapies in ADC-Bispecific Deal Worth Up To $1.25B
December 4, 2025
·
2 min read
·
Tristan Manalac
Manufacturing
Biotechs Secure Alternative Fill/Finish Capacity Amid Scrutiny of Novo Site
December 2, 2025
·
6 min read
·
Nick Paul Taylor
Series B
Novartis-Backed Protego Eyes Pivotal Amyloidosis Study With $130M Series B
December 1, 2025
·
1 min read
·
Tristan Manalac
Layoff Tracker
Valneva Terminates 30 Amid Site Closure
December 1, 2025
·
92 min read
·
BioSpace Editorial Staff
